{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:53:13Z","timestamp":1765828393762,"version":"3.37.3"},"reference-count":40,"publisher":"BMJ","issue":"2","funder":[{"name":"Orphazyme A\/S","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"FDA Office of Orphan Products Development","award":["R01FD004809"],"award-info":[{"award-number":["R01FD004809"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2024,6,12]]},"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To evaluate the validity, reliability, responsiveness and meaningful change threshold of the Inclusion Body Myositis (IBM) Functional Rating Scale (FRS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data from a large 20-month multicentre, randomised, double-blind, placebo-controlled trial in IBM were used. Convergent validity was tested using Spearman correlation with other health outcomes. Discriminant (known groups) validity was assessed using standardised effect sizes (SES). Internal consistency was tested using Cronbach\u2019s alpha. Intrarater reliability in stable patients and equivalence of face-to-face and telephone administration were tested using intraclass correlation coefficients (ICCs) and Bland-Altman plots. Responsiveness was assessed using standardised response mean (SRM). A receiver operator characteristic (ROC) curve anchor-based approach was used to determine clinically meaningful IBMFRS change.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 150 patients, mean (SD) IBMFRS total score was 27.4 (4.6). Convergent validity was supported by medium to large correlations (r<jats:sub>s<\/jats:sub>modulus: 0.42\u20130.79) and discriminant validity by moderate to large group differences (SES=0.51\u20131.59). Internal consistency was adequate (overall Cronbach\u2019s alpha: 0.79). Test\u2013retest reliability (ICCs=0.84\u20130.87) and reliability of telephone versus face-to-face administration (ICCs=0.93\u20130.95) were excellent, with Bland-Altman plots showing good agreement. Responsiveness in the worsened group defined by various external constructs was large at both 12 (SRM=\u22120.76\u2009to \u22121.49) and 20 months (SRM=\u22121.12\u2009to \u22121.57). In ROC curve analysis, a drop in at least two IBMFRS total score points was shown to represent a meaningful decline.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>When administered by trained raters, the IBMFRS is a reliable, valid and responsive tool that can be used to evaluate the impact of IBM and its treatment on physical function, with a 2-point reduction representing meaningful decline.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02753530\">NCT02753530<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1136\/jnnp-2024-333617","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T04:47:36Z","timestamp":1719982056000},"page":"122-131","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Measurement properties of the Inclusion Body Myositis Functional Rating Scale"],"prefix":"10.1136","volume":"96","clinical-trial-number":[{"clinical-trial-number":"nct02753530","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04789070","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05721573","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02753530","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04789070","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05721573","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04789070","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05721573","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02753530","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1567-3548","authenticated-orcid":false,"given":"Sharfaraz","family":"Salam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara","family":"Symonds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Doll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Rousell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Randall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"Lloyd-Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacie","family":"Hudgens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Guldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Herbelin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J","family":"Barohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7148-989X","authenticated-orcid":false,"given":"Mazen M","family":"Dimachkie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8411-7972","authenticated-orcid":false,"given":"Pedro M","family":"Machado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"key":"2025011602550656000_96.2.122.1","doi-asserted-by":"crossref","unstructured":"Machado PM , Ahmed M , Brady S , et al . Ongoing developments in sporadic inclusion body Myositis. Curr Rheumatol Rep 2014;16. doi:10.1007\/s11926-014-0477-9","DOI":"10.1007\/s11926-014-0477-9"},{"key":"2025011602550656000_96.2.122.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0186-x"},{"key":"2025011602550656000_96.2.122.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2022.101761"},{"key":"2025011602550656000_96.2.122.4","doi-asserted-by":"publisher","DOI":"10.3233\/JND-150138"},{"key":"2025011602550656000_96.2.122.5","doi-asserted-by":"crossref","unstructured":"Ahmed M , Machado PM , Miller A , et al . Targeting protein homeostasis in sporadic inclusion body Myositis. Sci Transl Med 2016;8. doi:10.1126\/scitranslmed.aad4583","DOI":"10.1126\/scitranslmed.aad4583"},{"key":"2025011602550656000_96.2.122.6","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30280-0"},{"key":"2025011602550656000_96.2.122.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30200-5"},{"key":"2025011602550656000_96.2.122.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00275-2"},{"key":"2025011602550656000_96.2.122.9","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/0q2voe"},{"key":"2025011602550656000_96.2.122.10","doi-asserted-by":"crossref","first-page":"e865","DOI":"10.1212\/WNL.0000000000200776","article-title":"Longitudinal changes in MRI muscle Morphometry and composition in people with inclusion body Myositis","volume":"99","author":"Laurent","year":"2022","journal-title":"Neurology"},{"key":"2025011602550656000_96.2.122.11","doi-asserted-by":"crossref","unstructured":"Roy B , Lucchini M , Lilleker JB , et al . n.d. Current status of clinical outcome measures in inclusion body Myositis: a Systematised review. Clinical and Experimental Rheumatology. doi:10.55563\/clinexprheumatol\/ifacv3","DOI":"10.55563\/clinexprheumatol\/ifacv3"},{"key":"2025011602550656000_96.2.122.12","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2018.33"},{"key":"2025011602550656000_96.2.122.13","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200168","article-title":"Study to assess content validity and Interrater and Intrarater reliability of the inclusion body Myositis functional rating scale","volume":"13","author":"Symonds","year":"2023","journal-title":"Neur Clin Pract"},{"key":"2025011602550656000_96.2.122.14","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20958"},{"key":"2025011602550656000_96.2.122.15","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0022-510X(97)00237-2","article-title":"Performance of the Amyotrophic lateral sclerosis functional rating scale (ALSFRS) in multicenter clinical trials","volume":"152 Suppl 1","author":"Cedarbaum","year":"1997","journal-title":"J Neurol Sci"},{"key":"2025011602550656000_96.2.122.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2013.02.010"},{"key":"2025011602550656000_96.2.122.17","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11459-3"},{"key":"2025011602550656000_96.2.122.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2013.08.007"},{"key":"2025011602550656000_96.2.122.19","doi-asserted-by":"crossref","unstructured":"Dimachkie MM , Hanna M , Machado P , et al . n.d. Phase II study of Arimoclomol in IBM FDA-OOPD. Rrnmf 2. doi:10.17161\/rrnmf.v2i3.15728","DOI":"10.17161\/rrnmf.v2i3.15728"},{"key":"2025011602550656000_96.2.122.20","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-325141"},{"key":"2025011602550656000_96.2.122.21","unstructured":"Ware J , Snow K , Kosinski M , et al . SF-36 health survey manual and interpretation guide. In: In: Institute BTH. New England Medical Center Hospitals, 1993."},{"key":"2025011602550656000_96.2.122.22","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-1-20"},{"key":"2025011602550656000_96.2.122.23","doi-asserted-by":"publisher","DOI":"10.1002\/mus.22321"},{"key":"2025011602550656000_96.2.122.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.02.006"},{"key":"2025011602550656000_96.2.122.25","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-020-01179-5"},{"key":"2025011602550656000_96.2.122.26","unstructured":"Cohen . Statistical Power Analysis for the Behaviors Science. 2nd edn. Hillsdale: Laurence Erlbaum Associates, 1988."},{"key":"2025011602550656000_96.2.122.27","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-54"},{"key":"2025011602550656000_96.2.122.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2008.07.009"},{"key":"2025011602550656000_96.2.122.29","doi-asserted-by":"publisher","DOI":"10.2307\/2533545"},{"key":"2025011602550656000_96.2.122.30","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3"},{"key":"2025011602550656000_96.2.122.31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208274"},{"key":"2025011602550656000_96.2.122.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2022.08.005"},{"key":"2025011602550656000_96.2.122.33","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00242-2"},{"key":"2025011602550656000_96.2.122.34","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26521"},{"key":"2025011602550656000_96.2.122.35","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead194"},{"key":"2025011602550656000_96.2.122.36","first-page":"399","article-title":"Paucity of Bulbar function measures in inclusion body Myositis trials. reply to: Current status of clinical outcome measures in inclusion body Myositis: a Systematised review","volume":"41","author":"(Focht) Garand","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"2025011602550656000_96.2.122.37","doi-asserted-by":"publisher","DOI":"10.1097\/MOO.0000000000000922"},{"key":"2025011602550656000_96.2.122.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120228"},{"key":"2025011602550656000_96.2.122.39","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24562"},{"key":"2025011602550656000_96.2.122.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2014.04.001"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2024-333617","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T10:55:58Z","timestamp":1737024958000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2024-333617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1,16]]},"published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1136\/jnnp-2024-333617"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2024-333617","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"type":"print","value":"0022-3050"},{"type":"electronic","value":"1468-330X"}],"subject":[],"published":{"date-parts":[[2024,7,2]]}}}